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Purpose: Diosgenin (DSG) is the precursor of steroid hormones and plays a crucial part in
the proliferation of various carcinomas including human colorectal cancer and gastric
carcinoma. Nevertheless, its specific features and mechanisms in human cholangiocarcinoma
(CCA) remain unknown.
Methods: MTS assay, colony-forming assay, and EdU assay were performed to determine the
role of DSG on the progression of human CCA cells. The distributions of cell cycle, the ratio of
apoptosis, and the mitochondrial membrane potential (ΔΨm) were studied by flow cytometry
(FCM). AO/EB andHoechst 33258 staining were performed to observe themorphological features
of cell apoptosis. TEM was performed to observe the ultrastructures of QBC939 and HuCCT1
cells. The mRNA and protein expression of mitochondrial apoptotic pathway and GSK3β/β-
catenin pathway were further confirmed by qPCR and Western blotting. The xenograft tumor
model of HuCCT1 cells was built. Immunohistochemistry of tumor tissues was performed.
Results: Our results indicated that DSG inhibited the progression of six CCA cell lines. In
vivo tumor studies also indicated that DSG significantly inhibited tumor growth in xenografts
in nude mice. The expression of mitosis-promoting factor cyclinB1 was decreased along with
the elevating level of cell cycle inhibitor p21, resulting in arresting CCA cell cycles at G2/M
phase. Furthermore, DSG induced apoptosis with the increased expressions of cytosol cyto-
chrome C, cleaved-caspase-3, cleaved-PARP1 and the Bax/Bcl-2 ratio. Mechanistically, our
study showed that GSK3β/β-catenin pathway was involved in the apoptosis of CCA cells.
Thus, DSG might provide a new clue for the drug therapy of CCA.
Conclusion: In our data, DSG was found to have efficient antitumor potential of human
CCA cells in vitro and in vivo.
Keywords: diosgenin, cholangiocarcinoma, apoptosis, mitochondria, GSK3β/β-catenin
pathway
Introduction
Cholangiocarcinoma (CCA) is one of the common malignant tumors. Its typical
features include serious drug resistance and poor prognosis.1 Now surgery remains
to be the primary treatment of CCA, along with radiotherapy and chemotherapy.
Most patients are diagnosed in an advanced stage with metastasis.2,3 These obser-
vations emphasize the need to develop effective therapies against CCA.
Diosgenin (DSG) is a naturally occurring steroidal sapogenin, a major bioactive
steroidal saponin found in natural plants, including tuber of wild yam (Dioscorea
villosa Linn) and seed of fenugreek (Trigonella Foenum graecum Linn).4,5 As the
main precursor of steroidal hormones, DSG is of great importance in pharmaceutical
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industry.6 Further, it is used in various human diseases, such
as cancer, hypercholesterolemia, inflammation.7 Its functions
include anti-inflammation, anti-infection, anticoagulation,
anti-tumor, liver protection, and prevention of bone loss.8–11
In recent years, the anti-tumor role of DSG has been found in
colon cancer, squamous cell carcinoma.12–19 However, the
role of DSG on CCA is currently unknown.
Two common pathways of apoptosis are death receptor
pathway andmitochondrial pathway.Mitochondrial dysfunc-
tion is an important marker. Stimulation caused the change of
membrane permeability, then result in the loss of ΔΨm.
Then, Bcl-2 family is regulated, followed by the cleavage
of Caspase. With it, PARP proteins are cleaved, which
induces the occurrence of apoptosis.
Substantial attention has been focused on the ectopic
activation of the GSK3β⁄β-catenin signaling in various
diseases, including CCA. In the existence of Wnt ligands,
β-catenin accumulates, enters into the nucleus, and then
initiates transcription. On the other hand, when without
Wnt ligands, β-catenin binds to the destruction complex.
Next, β-catenin is phosphorylated and degraded.
In this study, DSG was found to exert the remarkable
antitumor potential of human CCA cells in vitro and in vivo.
Materials And Methods
Reagents
Diosgenin, RIPA buffer was obtained from Sigma Aldrich (St.
Louis,MO, USA). RPMI-1640, DMEMmedium, fetal bovine
serum (FBS), trypsin, penicillin, and streptomycin were pur-
chased from Gibco (Rockville, MD, USA). PI (propidium
iodide), Annexin V-FITC/PI apoptosis detection kit, z-VAD-
fmk, MTS, Hoechst 33258, and AO/EB (acridine orange/ethi-
dium bromide) were purchased from Abcam (Cambridge,
United Kingdom). 5-Ethynyl-2-deoxyuridine (EdU) was
obtained from RiboBio (Guangzhou, China). The primary
antibodies against GAPDH, Bax, Bcl-2, Caspase- 3, p21,
PARP-1, cytochrome c (CYT C), COX IV, β-catenin and
GSK3β were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Other antibodies were from Abcam.
Hematoxylin–Eosin Staining Kit was from Solarbio (Beijing,
China). The EliVision kit was from Maixin Biotech (Fuzhou,
China).
Cell Culture And Treatment
The human CCA cell lines HuCCT1, QBC939, SK-ChA-
1, HuH28, RBE, and Mz-ChA-1 were purchased from the
Cell Bank of Type Culture Collection of Chinese Academy
of Sciences (Shanghai, China). Cell lines were cultured in
RPMI-1640 or DMEM medium with 10% FBS, 100 U/mL
penicillin and 100 μg/mL streptomycin. Cells were incu-
bated under 37°C, 5% CO2. DSG was dissolved with
anhydrous ethanol, and diluted to different concentrations
with medium.
Cell Viability Analysis
Cell survival was analyzed by MTS assay. Briefly, cells
were seeded at the density of 5 × 103 cells/well on 96-well
microplates. Next day, cells were incubated with DSG of
different concentrations (0, 10, 20, 40, 80 μM). After 24 h,
48 h or 72 h, 20 µl MTS was added to each well contain-
ing 100 µl medium. The cells were incubated at 37°C for 4
hrs. Finally, the absorbance values were measured at 490
nm by a microplate reader (Molecular Devices).
Cell survivalð%Þ¼ðAsampleAblankÞ=ðAcontrolAblankÞ
100%
AO/EB And Hoechst 33258 Staining
QBC939 and HuCCT1 cells were seeded on the six-well
plates overnight and then treated with DSG of different
concentrations (0, 5, 10, 20, 40 μM). After 24 h, cells were
washed with PBS and incubated with 10 μg/mL AO/EB.
For another staining, cells were exposed to 10 μg/mL
Hoechst 33258. Then, morphological changes of cells
were photographed.
Cell Colony Formation Assay
Cells were seeded at a density of 500 cells/well on 6 cm
plates. Cells of control group were incubated with fresh
medium, and the other cells were treated with DSG (0, 5,
10, 20, 40 μM), respectively. Twelve days later, cells were
fixed with methanol for 15 min and then stained with 0.1%
crystal violet, and counted.
EdU Assay
A total of 5 × 103 cells were seeded on each well of a 96-
well plate overnight. Next day, cells were incubated with
100 μL EdU solution (50 μM) for 2 h at 37°C. Then, cells
were fixed in 4% paraformaldehyde at room temperature
for 30 min, followed by permeabilization with 0.5% Triton
X-100. Subsequently, the cells were stained with 1 ×
Apollo reaction mixture for 30 min. Finally, the nuclei
were stained with Hoechst 33342. Images were taken
using a fluorescence microscope.
Mao et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
OncoTargets and Therapy 2019:129094
Cell Cycle Analysis
CCA cells were treated with DSG for 24 h, then col-
lected and washed. Then, 70% ethanol was added in
cells for fixation. Next, cells were resuspended, and
incubated with 5 μL of 10 mg/mL RNase at 37°C for
30 min. After that, DNA was treated with 5 μL of 10
mg/mL PI for 30 min at 4°C without light. The DNA
content were monitored by a flow cytometer (FC500,
Beckman Coulter), and the data were performed with
ModFit LT 3.3 software.
Annexin V-FITC/PI Staining
Cell apoptosis was evaluated using Annexin V/PI apop-
tosis detection kit (Abcam) using the instruction book
and examined by flow cytometry. Briefly, cells were
seeded on the six-well plates and incubated with DSG
for 24 h, then trypsinized, and resuspended using the
binding buffer. Subsequently, 5 μL of Annexin V-FITC
and 5 μL of PI were added and incubated for 15 min.
Apoptotic cells were analyzed by an FC500 flow
cytometer.
Determination Of Δψm
The treated cells were collected and incubated with JC-1
dye for 1 h. Then, the ΔΨ m was quantitatively measured
and analyzed by an FC500 flow cytometer. In a general
way, the proportion of JC-1 fluorescence by red/green
reflects the change of ΔΨm.
Observation Of Cells With Transmission
Electron Microscopy (TEM)
Cells were fixed and dehydrated, then cut into ultrathin
sections. Then, the sections were stained with saturated
uranyl acetate and lead citrate. The ultrastructure of cells
and mitochondria was photographed under TEM (Tecnai
G2 Spirit, FEI).
Cytochrome C (CYT C) Release Assay
Mitochondria were isolated from cells according to Cell
Mitochondria Isolation Kit (Beyotime, China).
Western Blot
The CCA cells were collected and lysed. The proteins
were separated by SDS-PAGE and transferred to PVDF
membranes. Then, primary antibodies and secondary
antibodies were added. The immunoreactive products
were detected using enhanced chemiluminescence
(Advansta).
Quantitative Real-Time PCR (qPCR)
Total RNA was extracted from the CCA cells and rever-
sely transcribed into cDNA. The measurement was oper-
ated on an ABI Prism7500 system (Bio-Rad) using the
Fast SYBR Green Master Mix kit (Tiangen, China). The
primers used are in Table 1.
Animal Model
HuCCT1 cells were used to build animal model. Nude mice
(BALB/c) were purchased from SLAC Laboratory Animal
(Shanghai, China). HuCCT1 cells (3 × 106) were subcuta-
neously injected into the right oxter of mice, respectively.
Tumor volumes were calculated: A×B2/2(A and B, respec-
tively, represent the long and short diameter of the trans-
planted tumor). The control groups and treated groups
received solvent and 50 mg/kg DSG, respectively (every 2
days, intragastric administration, n = 6). All of the animal
experiments were approved by the Animal Ethics
Committee of Xiamen University. All experimental proce-
dures involving animals were performed in accordance with
animal protocols approved by the Laboratory Animal
Center of Xiamen University.
The tumor volume (day n) was calculated using relative
tumor volume (RTV=Vt/V0; Vt is the volume of the trans-
planted tumor measured each time, and V0 is the volume of
transplanted tumor measured when grouping drugs.). T/C
(%), relative tumor proliferation rate used the formula T/C
(%) = mean RTV of the treated group/mean RTV of the
control group × 100%.
Statistical Analysis
All the experiments were repeated three times, and all the
data were expressed as the mean ± standard deviation (SD)
and studied using IBM SPSS 22.0 software.
Table 1 Primers Of Real-Time Fluorescence Quantitative PCR
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DSG Inhibited CCA Cells Proliferation
And Colony Formation
The structure of DSG was shown in Figure 1A.12 We
examined the efficacy of DSG on CCA cell lines
(Figure 1B), and the data exhibited that DSG suppressed
all six CCA cell lines in a dose- and time-dependent
manner. QBC939 and HuCCT1 cell lines were employed
for further study. The IC50 values were shown in Table 2.
Furthermore, the colony-forming number of these two cell
lines was significantly reduced by DSG compared with
control (Figure 1C). After the initial cytotoxicity, DSG
did not seem to affect the capability of the cells that still
alive to grow and form the colony. Moreover, the results of
EdU assays illustrated that the DNA synthesis of CCA
cells was remarkably decreased in DSG-treated cells
(Figure 1D). Taken together, those data indicated that
DSG significantly suppressed the malignancy of CCA
cells in vitro.
DSG Induced Cell Cycle Arrest In CCA
Cells
The distributions of cell cycle were studied by flow cyto-
metry (FCM). The ratio of cells in G2/M phase increased,
implying that DSG arrested CCA cells at G2/M phase
(Figure 2A). For QBC939 and HuCCT1 cell lines, the
percentages of cells in G2/M phase increased from 8.06
± 1.99% to 20.52 ± 2.17%, and 7.79 ± 0.56% to 16.70 ±
3.16%, respectively. Meanwhile, the protein and mRNA
levels of cyclinB1 decreased after the treatment of DSG
(Figure 2B and C), which were necessary for the transition
of G2/M phase. Besides, the expression of cell cycle
inhibitor P21 increased slightly in QBC939 cells, but had
no significant differences in HuCCT1 cells.
DSG Induced Cell Apoptosis In Vitro
AO/EB and Hoechst 33258 staining indicated the typical
morphological features of cell apoptosis with the treatment
DSG (Figure 3A and B). For Hoechst 33258 staining,
DSG-treated cells exhibited brighter blue light than con-
trol, suggesting the chromatin condensation of nuclei. For
AO/EB staining, the control cells showed green fluores-
cence and cell structures were intact, while treated cells
emitted orange and red fluorescence.
TEM was performed to observe the ultrastructures of
QBC939 and HuCCT1 cells. For both cell lines, we could
observe the normal cell morphology in the control sample:
integrated cell nucleus and diffused chromatin. On the
other hand, DSG-treated sample exhibited typical apopto-
tic morphology: cell body and nucleus shrinkage, the
chromatin condensed, separated and moved to the inside
edge of nuclear envelope (Figure 3C). What is more,
mitochondria were swollen and their cristae were broken
after DSG treatment.
The FCM data were used to determine the ratio of
apoptosis with double staining. With the increasing con-
centrations of DSG, the rates of apoptosis of QBC939 cells
were raised from 6.90 ± 0.48% to 19.38 ± 1.27%, and
HuCCT1 cells were from 1.67 ± 0.33% to 27.33 ± 1.97%
(Figure 3D). The influence of DSG on ΔΨm was also
studied using FCM. With the DSG concentration
increased, the rates of depolarization raised from 3.04 ±
0.71% to 41.79 ± 1.79%, and from 2.48 ± 0.47% to 53.13
± 1.78%, respectively (Figure 3E). It suggested the col-
lapse of ΔΨm in CCA cells.
The Mitochondria-Mediated Intrinsic
Pathway And GSK3β/Β-Catenin Pathway
Involved In The Antitumor Activity Of
DSG In CCA Cells
Based on the changes in morphology and ΔΨm of mito-
chondria with DSG treatment, we further evaluated the
expression of proteins. Western blot data indicated that
DSG treatment elevated the ratio of Bax/Bcl-2 and acti-
vated PARP-1, Caspase-3. Besides, CYT C released from
mitochondria to cytoplasm (Figure 4A and B). The
Caspase inhibitor z-VAD-fmk (20 μM) significantly atte-
nuated the DSG-induced cell apoptosis (Figure 4C). Our
results suggested that DSG induced apoptosis of CCA
cells via activation of Caspases.
A large amount of oncogenic factors induce ectopic
activation of the GSK3β⁄β-catenin signaling in various
tumors, including CCA. To characterize the effect of
GSK3β/β-catenin signaling on the antitumor activity
induced by DSG, we detected related proteins of this path-
way (Figure 4D and E). The results showed that the
phosphorylation level of GSK3β at Ser-9 decreased and
the phosphorylation at Tyr-216 increased, indicating its
activation, which could cause the degradation of β-catenin.
Some results of QBC939 cells were not as obvious as
HuCCT1 cells. We came to a conclusion that the suppres-
sion of GSK3β/β-catenin pathway might be responsible for
the DSG-induced apoptosis.
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Figure 1 Diosgenin (DSG) inhibited the cell proliferation of cholangiocarcinoma (CCA). (A) The structure of DSG. (B) The role of DSG on the cell survival of CCA cells
using MTS assay. (C) Colony-formation assays were performed in QBC939 and HuCCT1 cells treated with DSG. The relative number of colonies was quantified. (D) EdU
assay was used to assess DNA synthesis of DSG-treated cells (left). Random 10 visions were quantified (right). *P < 0.05 and **P < 0.01.
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DSG Suppressed The Proliferation Of
CCA Cell In Xenograft
We built the xenograft tumor model of HuCCT1 cells. The
body weight of mice showed no remarkable changes
(Figure 5A), while tumor weights and volumes decreased
apparently (Figure 5D and E). To verify the non-toxicity of
DSG, the internal organs of animal were weighed and
stained with HE staining (Figure 5B and C). The data
indicated that viscus had no significant changes after
DSG treatment. In the treatment group, for example, all
the hepatocytes showed obvious nucleus structure, no
punctate or patchy necrosis, and swelling. The typical
alveolar reticular structure was seen in all lung tissues.
The contrast between the nuclei and cytoplasm was
obvious, and the nuclei were clearly visible. By contrast,
HE staining of xenograft tumors in DSG-treated group
exhibited classic apoptotic trait: condensed chromatin
and pyknotic nuclei (Figure 5F). Besides, IHC analysis
indicated that PCNA and Ki67 positive cells were signifi-
cantly decreased in the xenograft tumor from DSG-treated
group (Figure 5G). Furthermore, our data revealed that
DSG greatly inhibited the progression of HuCCT1 xeno-
graft tumors (T/C% = 36.6%). The results of Western blot
(Figure 5H) are in line with our previous results in cell
culture, showing the involvement of mitochondria-
mediated apoptosis pathway and GSK3β/β-catenin path-
way in DSG treatment.
Discussion
Previously reports have demonstrated that DSG inhibits the
malignancy of various carcinoma.20–22 However, its func-
tions on CCA need to be studied further. DSG, a natural
steroidal saponin, is an important precursor for the synthesis
of steroidal hormone, which has high medicinal value.23,24
This experiment proved that DSG inhibited the malignancy
of CCA cells through inducing G2/M phase arrest and
mitochondria-mediated apoptosis.
CyclinB1 is a regulatory protein in G2 checkpoint and
plays important roles in mitotic initiation regulation and cell
cycle regulation.25 CyclinB1 overexpression can promote G2/
M phase transformation, accelerate cell cycle progression, and
contribute to malignant cell transformation. P21 is a cell cycle
protein-dependent kinase inhibitor, which can inhibit the activ-
ity of most cyclin-dependent kinase (CDK).26 It can not only
inhibit cell proliferation but also trigger cell cycle arrest. P21
can promote cyclinB1 nuclear transposition and block cells at
G2/M stage.27 The expression changes of p21 and cyclinB1 in
DSG-treated CCA cells were studied by Western blot and
qPCR. The results illustrated that DSG remarkably decreased
the expression of cyclinB1. So we speculated that DSG
induced G2/M phase arrest, affected the smooth progress of
the cell cycle, and thus suppressed the progression of CCA
cells. However, the exactmechanism needs further exploration
and verification. The cell proliferation is regulated through cell
cycle and the occurrence of tumor may lie in deregulation of
cell cycle, directly resulted from the abnormal of the complex
of CDK. The catalytic activities of CDKs are modulated by
interactions with cyclins and CDK inhibitors (CKIs).28
Whereas most cyclins promote CDK activity, CKIs suppress
CDK activity. CKIs are divided into two classes based on their
structure and specificity. The Ink4 family members, including
p16, p15, p18, and p19, mainly target Cdk4 and Cdk6. On the
other hand, p21, p27, and p57 are the members of Cip/Kip
family. They are more promiscuous and broadly interfere with
the activities of cyclin D-, E-, A- and B-dependent kinase
complexes.29 In addition, previous studies have found that
more than 10 microRNAs were involved in cell cycle regula-
tion. Among them, mir-1-2 and mir-34 targeted CDK4, which
induced cell cycle arrest in G1 phase.30 Therefore, the regula-
tion of cell cycle is a complex process, and many studies need
to be carried out.
Apoptosis is a process of multi-pathway regulation. For
example, it includes Caspase activation, cleaved-PARP
elevation, phosphatidylserine overturning on cell mem-
brane, and chromatin condensation.31–36 According to the
results of AO/EB, Hoechst 33258 fluorescent staining and
Annexin V-FITC/PI staining, DSG inhibited the progres-
sion and induced apoptosis of CCA cells in vitro.
Endogenous mitochondrial pathway is crucial to cell
apoptosis regulation. The endogenous approach in many
events is closely related to mitochondrial, such as the
destruction of mitochondria outer membrane, the release
of Cyt C, the participation of apoptosis-related proteins.37
Table 2 The IC50 Of Diosgenin On Cholangiocarcinoma Cell
Lines
IC50 (μM)
24 h 48 h 72 h
HuCCT1 12.82 ± 0.52 11.99 ± 0.45 11.57 ± 0.04
QBC939 21.88 ± 0.79 19.33 ± 0.20 17.29 ± 0.13
SK-ChA-1 13.55 ± 0.38 11.11 ± 0.43 6.24 ± 0.50
HuH28 25.04 ± 3.08 14.71 ± 2.39 8.90 ± 0.65
RBE 25.79 ± 2.15 20.42 ± 2.58 13.56 ± 0.88
Mz-ChA-1 22.70 ± 0.33 19.35 ± 0.59 15.75 ± 0.36
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Figure 2 The change of cell cycle distribution after treatment with DSG. (A) Cells were treated with DSG at various concentrations for 24 h, and examined by FCM.
Representative results were shown (left). Histogram showed the quantified data (right). (B, C) The qPCR and Western blot analysis for the expression of cyclinB1 and P21.
*P < 0.05 and **P < 0.01.
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Figure 3 Cell apoptosis induced by DSG in CCA cells. (A, B) AO/EB and Hoechst 33258 staining of QBC939 and HuCCT1 cells. (C) The ultrastructures of cells and
mitochondria in CCA cells were observed by TEM after DSG treatment. (D) FCM analysis of apoptosis using Annexin V-FITC/PI staining. Histogram showed the rates of
apoptotic cells. (E) FCM analysis of ΔΨm. *P < 0.05, **P < 0.01, and ***P < 0.001.
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Both Caspase family proteins and Bcl-2 family proteins
are crucial in this process. Detecting the apoptosis-related
proteins by Western blot, the proportion of Bax/Bcl-2,
Caspase-3 and Cleaved-PARP was increased in a dose-
dependent manner. The data also showed that CYT C
released from mitochondria to the cytoplasm. Under the
existence of Caspase inhibitors z-VAD-fmk, MTS results
revealed remarkably increase cell vitality of HuCCT1
cells. Above all, we speculated that DSG induced CCA
cell apoptosis through the intrinsic mitochondrial pathway.
Interestingly, we found that GSK3β/β-catenin pathway
involved in apoptosis inducing of CCA cells. The results
Figure 4 The involvement of intrinsic mitochondria pathway and GSK3β/β-catenin pathway in the DSG treatment. (A, B) Western blot for cell lysis collected to analyze the
expression of mitochondria pathway–related proteins. (C) Cell survival rates were studied after treating with DSG in the presence or absence of 20 μM z-VAD-fmk. (D, E)
GSK3β/β-catenin pathway was detected. **P < 0.01, and ***P < 0.001.
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Figure 5 DSG suppressed the growth of CCA in vivo without toxic to viscera. (A) The variational curve of nude mice body weight. (B) The mean weights of viscera after
administration. (C, F) The HE staining of viscera and tumors. (D) Mean tumor weight at the end of 20 days. (E) Mean tumor volume on the indicated days. (G) IHC analysis
of PCNA and Ki67 in the xenograft tumor of nude mice. (H) Western blot assay to confirm the expression of proteins. *P < 0.05 and **P < 0.01.
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showed that the phosphorylation level of GSK3β at Ser-9
reduced and the phosphorylation at Tyr-216 increased,
indicating its activation. Therefore, this activation pro-
moted the ubiquitin and degradation of β-catenin, and
ultimately affected the CCA cell proliferation. To sum
up, DSG might influence the progression and apoptosis
of CCA cells through GSK3β/β-catenin signaling.
The xenograft assay in nude mice demonstrated DSG
effectively inhibited the growth of CCA in vivo without
obvious toxic and side effects. Down-regulated PCNA and
Ki67 protein expression of DSG implied decreased prolif-
eration ability. The expression of p21 and the Bax/Bcl-2
proportion was increased. And the expressions of cleaved
Caspase-3 and PARP-1 were significantly enhanced by
DSG too. Besides, the changes in GSK3β/β-catenin path-
way were consistent with the results in vitro. Generally,
our study proved that the DSG suppressed CCA cells and
induced apoptosis in vitro and in vivo. From a natural
source, DSG had remarkable potential to become one of
the chemotherapy drugs in clinical.
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